Breast cancer in young women is a devastating and complex disease. Breast cancer in women under 40 strikes when these women are at the peak of their reproductive years, family life and careers and still have many years ahead of them to suffer the long-term effects of treatment or the consequences of recurrent disease. The etiology of breast cancer in this population is poorly understood and most clinical trials focus on women who are over the age of 40, thus little evidence-based data is available about the optimal management of these patients. Further research is much needed in this field. This conference is an opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy and fertility preservation in young women with breast cancer.


LEARNING OBJECTIVES 
• In depth learning of various aspects of breast cancer in young women
• Importance of multi-disciplinary management 
• Management of difficult clinical cases


MAIN TOPICS 
• Hereditary breast cancer
• Diagnostic tools in young women
• Local therapy
• Systemic therapy
• Pregnancy and breast cancer
• Fertility preservation
• Psychosocial aspects
• Management of side effects
• Case discussions


TARGET AUDIENCE 
• Medical oncologists
• Surgeons
• Gynaecologists
• Radiation oncologists
• Breast radiologists
• Onco-geneticists
• Phatologists
• Nurses 
• Patient advocates 

CHAIRS
F. Cardoso, Champalimaud Cancer Center, Lisbon, PT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
A.H. Partridge, Dana-Farber Cancer Institute, Boston, US
B. Kaufman, Sheba Medical Center, Tel Hashomer, IL


FACULTY (as of February 2014)
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL
A. Costa, European School of Oncology, Milano, IT
E. Evron, Assaf Hospital, Zerifin, IL
L. Fallowfield, Brighton & Sussex Medical School, Brighton, GB
E. Friedman, Sheba Medical Center, Tel Hashomer, IL
J. Garber, Dana Farber Cancer Institute, Boston, US
K. Gelmon, BC Cancer Agency, Vancouver, CA
N. Harbeck, Hospital of the University of Munich (LMU), Munich, DE
E. Levy Lahad, Shaare Zedek Medical Center, Jerusalem, IL
S. Loibl, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, DE
E. Bar-Meir, Plastic Surgeon, Haifa, IL
D. Meirow, Sheba Medical Center, Ramat Gan, IL
E. Mozer, Champalimaud Foundation, Lisbon, PT
S. Paluch-Shimon, Sheba Medical Center, Ramat Gan, IL
F.A. Peccatori, European Institute of Oncology, Milano, IT
T. Sella, Hadassah Medical Organization - Ein-Kerem Hospital, Jerusalem, IL
M. Sklair-Levy, Sheba Medical Center, Tel Hashomer, IL
M. Ziv, Israel Cancer Association, Givatayim, IL

Information will be available soon.

Submission Info

Participants are invited to submit an abstract on breast cancer in young women, in one of the following categories:

• Basic/Translational Research; 
• Clinical Research; 
• Advocacy and Nursing 
 

Instructions:
• The abstract should be limited to 2000 characters, including the title
• The title should be in lower case letters
• Each author should be listed with First Name, followed by Family Name
• The first author should be underlined (first author = corresponding author and presenter)
• List affiliations after the authors’ list
• The full address with e-mail address, phone and fax numbers of the first author (+ corresponding author and presenter) must be provided. The first author will receive an acknowledgement of receipt and all subsequent  
  communication by e-mail.
• For abstracts accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Conference.
• It is the responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.


The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by 25 July to the first author who will be required to register to the Conference (early registration deadline: 3 August).